お知らせ • Mar 19
X Bioscience Public Company Limited, Annual General Meeting, Apr 30, 2026 X Bioscience Public Company Limited, Annual General Meeting, Apr 30, 2026, at 13:00 SE Asia Standard Time. New Risk • Mar 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -฿79m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-฿79m free cash flow). Share price has been highly volatile over the past 3 months (36% average weekly change). Earnings have declined by 10% per year over the past 5 years. Shareholders have been substantially diluted in the past year (254% increase in shares outstanding). Market cap is less than US$10m (฿63.0m market cap, or US$2.03m). Minor Risk Revenue is less than US$5m (฿130m revenue, or US$4.2m). Reported Earnings • Mar 01
Full year 2025 earnings released: ฿1.13 loss per share (vs ฿1.41 loss in FY 2024) Full year 2025 results: ฿1.13 loss per share. Revenue: ฿129.7m (down 59% from FY 2024). Net loss: ฿451.9m (loss widened 74% from FY 2024). お知らせ • Feb 27
X Bioscience Public Company Limited Announces Resignation of Tom Chalernkarnchana as Independent Director, Effective 25 February 2026 X Bioscience Public Company Limited acknowledged the resignation of Mr. Tom Chalernkarnchana from his positions as Independent Director, Audit Committee Member, and Nomination and Remuneration Committee Member of the Company, effective from 25 February 2026 onwards. お知らせ • Feb 13
X Bioscience Public Company Limited Announces Board Changes At the Board of Directors' Meeting No. 2/2026 of X Bioscience Public Company Limited held on February 11, 2026 at 11:40 hrs. via electronic media in accordance with the Royal Decree on Electronic Meetings B.E. 2563 (2020) and other relevant laws, the meeting passed significant resolutions which are required to be reported to the Stock Exchange of Thailand, as follows: approved the appointment of Miss Thansuda Rungruang as a Director of the Company in replacement of Asst. Prof.Dr.Pattanant Petchchedchoo, who resigned. Ms. Thansuda Rungruang shall hold office for the remaining term of the resigned director (expiring at the 2027 Annual General Meeting of Shareholders). The appointment shall be effective from 11 February 2026 onward. Following the appointment the structure of the Board of Directors shall consists of the following list including the names and positions of individuals who will serve as Directors and/or Independent Directors of the Company:
Mr. Supoj Pannoi: Position: Chairman of the Board of Directors /Independent Director /Audit Committee. Miss Saowanee Khaoubol: Position: Vice Chairman of the Board of Directors /Director /Chief Executive Officer (Acting). Miss Naphat Tavisaengsiri: Position: Director. Mr. Amnart Lertpresertwong: Position: Director. Miss Thansuda Rungruang: Position: Director. Mr. Tom Chalermkarnchana: Position: Independent Director /Audit Committee /Nomination and Remuneration Committee. Mr. Yuthaveera Achawangkul: Position: Independent Director /Nomination and Remuneration Committee. Mr. Sarayut Rueangsuwan: Position: Independent Director /Chairman of the Audit Committee /Chairman of the Nomination and Remuneration Committee. お知らせ • Jan 08
X Bioscience Public Company Limited Appoints Directors, Effective December 22, 2025 X Bioscience Public Company Limited at the board of directors meeting held on December 22, 2025 in accordance with the Emergency Decree on Electronic Meetings B.E. 2563 (2020) and other applicable laws, the company hereby reports the following material resolutions to The Stock Exchange of Thailand as follows: Resolved to approve the appointment of 3 directors to replace the resigning directors as follows: Asst. Prof. Dr. Pattanant Petchchedchoo was appointed as Independent Director and Chairman of the Board of Directors, replacing Mr. Tanawat Ueasiripan, with a term of office equal to the remaining term of the resigning director (to expire at the Annual General Meeting of Shareholders for the year 2027). The appointment shall be effective from 22 December 2025 onwards. Mr. Supoj Pannoi was appointed as Independent Director and Member of the Audit Committee, replacing Mr. Sivaporn Chomsuwan, with a term of office equal to the remaining term of the resigning director (to expire at the Annual General Meeting of Shareholders for the year 2027). The appointment shall be effective from 22 December 2025 onwards. Mr. Amnart Lertpresertwong was appointed as Director, replacing Mr. Phurit Wongkham, with a term of office equal to the remaining term of the resigning director (to expire at the Annual General Meeting of Shareholders for the year 2026). The appointment shall be effective from 22 December 2025 onwards. Following the appointment of the above directors, the structure of the Company's Board of Directors shall comprise the following persons as Directors and/or Independent Directors of the Company: Asst. Prof. Dr. Pattanant Petchchedchoo, Independent Director /Chairman of the Board of Directors; Miss Saowanee Khaoubol, Director /Acting Chief Executive Officer; Miss Naphat Tavisaengsiri, Director; Mr. Amnart Lertpresertwong, Director; Mr. Yuthaveera Achawangkul, Independent Director /Nomination and Remuneration Committee; Mr. Sarayut Rueangsuwan, Independent Director /Chairman of the Audit Committee /Chairman of the Nomination and Remuneration Committee; Mr. Supoj Pannoi, Independent Director /Audit Committee; Mr.Tom Chalermkarnchana, Independent Director /Audit Committee /Nomination and Remuneration Committee. 